The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer

Anticancer Research

Volumn 20, Issue 2 A, 2000, Pages 735-740

  Muenchen, Heather J ^a   Quigley, Martha M ^a   Pilat, Mary Josephine P ^a   Lehr, Jeffrey E ^a   Brumfield, Susan K ^a   Mahoney, Michael ^a   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Combination chemotherapy; Dunning rat model; Gemcitabine; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; CHLORMETHINE DERIVATIVE; ESTRAMUSTINE; ETOPOSIDE; GEMCITABINE; PACLITAXEL; PYRIMIDINE ANTAGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL NUCLEUS; COULTER COUNTER; CYTOLYSIS; EXPERIMENTAL NEOPLASM; GROWTH INHIBITION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL DIVISION; CELL SURVIVAL; DEOXYCYTIDINE; DRUG SYNERGISM; ESTRAMUSTINE; ETOPOSIDE; HUMANS; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; RATS; TUMOR CELLS, CULTURED;

EID: 0034010628     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Landis SH, Murray T, Bolden S, and Wingo, PA: Cancer Statistics, 1999. CA Cancer J Clin 49: 6-29, 1999.
2. Ahrahamsson PA: The risks outweigh the benefits of radical prostatectomy in localized prostate cancer: The argument for. Eur Urol 29 (suppl 2): 19-23, 1996.
3. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB: Evaluation of the anti-tumor activity of gemcitabine (2',2'-Difluoro-2'-deoxycytidine). Cancer Res 50: 4417-4422, 1990.
4. Csoka K, Liliemark J, Larsson R and Nygren P: Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. Semin Oncol 22: 47-53, 1995.
5. Lund B, Kristjansen PEG, and Hansen HH: Clinical and preclinical activity of 2', 2'-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19: 45-55, 1993.
6. Blackstein M, Vogel CL, and Ambiner R: Phase II study of gemcitabine in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15: 135, 1996.
7. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, and Harris AL: Advanced breast cancer: phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995.
8. Lund B, Hansen OP, Theilade K, Hansen M, and Neijt J.P: Phase II study of gemcitabine (2',2'-diflurodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533, 1994.
9. Underhill C, Parnis FX, Highly M, Ahern J, Lund B, Kamby C, Carmichael J, Harper P, Williams C, Hirsch F, Hansen M, Smith C and Walling J: Phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer Ann Oncol 7: 69, 1996.
10. Neijt JP, Kaufman M, Bauknecht T, van Belle S, Jonat W, Piccart MJ, Thomas J, Wills JAMJ, Nooy MA and Gruhl CM: Gemcitabine in pretreated ovarian cancer. Ann Oncol 7: 70, 1996.
11. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA and Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynaecol Oncol 63: 89-93, 1996.
12. Anderson H, Lund B, Bach F, Thatcher N, Walling J, and Hansen HH: Single-agent activity of weekly gemcitabine in advanced small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826, 1994.
13. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D and Rugg TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540, 1994.
14. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B and Tarassoff PG: Phase II trial of gemcitabine (2',2'-diflurodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-34, 1994.
15. Moore M: Activity of gemcitabine in patients with advanced pancreatic carcinoma. Cancer 78: 633-638, 1996.
16. Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J, Franklin H and Kay SBA: Phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 543-547, 1994.
17. Pollera CF, Ceribelli A, Creeco M and Calabresi F: Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182-184, 1994.
18. DeLena M, Gridelli C, Lorusso V, Amadori D, Antimi M, Luporini G, Pollera C and Oliva C: Gemcitabine activity (objective responses and symptom improvement) in resistant stage IV bladder cancer. Proc Am Soc Clin Oncol 15: 246, 1996.
19. Moore MJ, Tannock I, Ernst S, Huan S and Murray N: Gemcitabine demonstrates promising activity as a single agent in the treatment of metastatic transitional cell carcinoma. Proc Am Soc Clin Oncol 15: 250, 1996.
20. Stadler WM, Kuzel TM, Ragahavan D, Roth B, Vogelzang NJ, Levine EL and Dorr FA: A phase II study of gemcitabine in bladder cancer Ann Oncol 7: 58, 1996.
21. Hui YF and Reitz J: Gemcitabine: A cytidine analogue active against solid tumors. Am J Health-Syst Pharm 54: 162-170, 1997.
22. Perng RP, Chen YM, Ming-Liu J, Tsai CM, Lin WC, Yang KY and Whang-Peng J: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15: 2097-2102, 1997.
23. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB and Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2', 2'-difluorodeoxycytidine. Mol Pharmacol 38: 567-572, 1990.
24. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2', 2'-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
25. VanHaperen VWTR, Veerman G, Vermorken JB and Peters GJ: 2', 2'-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharm 46: 762-766, 1993.
26. Peters GJ and Plunkett W: Introduction: Gemcitabine-status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Semin Oncol 24: S7-17-S7-23, 1997.
27. Carmichael J: The role of gemcitabine in the treatment of other tumours. Br J Cancer 78: 21-5, 1998.
28. Steward WP: Combination studies with gemcitabine in the treatment of non-small-cell lung cancer. Br J Cancer 78: 15-19, 1998.
29. Castellano D, Lianes P, Paz-Ares L, Tidalgo M, Guerra JA, Gomez-Martin C, Gomez H, Calzas J and Cortes-Funes H; A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advance non-small-cell lung cancer. Ann Oncol 9: 457-459, 1998.
30. Van Moorsel CJA, Veerman G, Vermorken JB, Voorn DA, Kroep JR, Bergman AM, Pinedo HM and Peters GJ: Mechanism of synergism between gemcitabine and cisplatin. In: Purine and Pyrimidine Metabolism in Man IX. Plenum Press, New York, 1998, pp.581-58.
31. Kanzawa F and Saijo N: In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 24: S7-8-S7-16, 1997.
32. Pedersen AG: Phase I studies of gemcitabine combined with carboplatin or paclitaxel. Semin Oncol 24: S7-64-S7-68, 1997.
33. Hanauske AR, Rassmann I, Depenbrock H, Thodtmann R, Blatter J, Rastetter J: Phase I trial of gemcitabine and etoposide in solid tumors. Proc Annu Meet Am Soc Clin Oncol 15: A1420, 1996.
34. Cronauer MV, Klocker J, Talasz H, Geisen FH, Hobisch A, Radmayr C, Bock G, Culig Z, Schirmer M, Reissigl A, Bartsch G and Konwalinka G: Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate 28: 172-181, 1996.
35. Pienta KJ and Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 149: 1622-5, 1993.
36. Pienta KJ, Esper PS and Smith DC: The oral regiment of cytoxan, prednisone and diethylstilbesterol (CPD) is an active, non-toxic treatment for patients with hormone refractory prostate cancer. Proc Annu Meet Am Soc Clin Oncol 16: A1104, 1997.
37. Pienta KJ and Smith DC: Paclitaxel, estramustine and etoposide in the treatment of hormone-refractory prostate cancer. Semin Oncol 24: S15-72-S15-77, 1997.
38. Pienta KJ, Naik H and Lehr JE: Effect of estramustine, etoposide and taxol on prostate cancer cell growth in vitro and in vivo. Urology 48: 164-170.
39. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H and Smith DC: A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology 50: 401-406, 1997.
40. Wiese TE, Kral LG, Dennis KE, Butler WB and Brooks SC: Optimization of estrogen growth response in MCF-7 cells. In Vitro Cell Dev Biol 28A: 595-602, 1992.
41. Butler WB: Preparing nuclei from cells in monolayer cultures suitable for counting and for following synchronized cells thru the cell cycle. Analytical Biochemistry 141: 70-73, 1984.
42. Panvichian R, Orth K, Pilat MJ, Day ML, Day KC, Yee C, Kamradt JM and Pienta KJ. Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line. Urology, in press , 1999.
43. Storniolo AM, Allerheiligen SRB, and Pearce HL. Preclinical, pharmacologic and phase I studies of gemcitabine. Semin Oncol 24: S7-2-S7-7, 1997.
44. Brachium BJM, van Dona GAMS, Vermorken JB, and Snow GB. Preclinical in vivo activity of 2'2'-difluro-deoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51: 211-214, 1991.
45. Peters GJ, Bergman AM, Ruin van Heparin VWT, Veerman G, Copier CM, and Brachium BJM. Interactions between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22: S11-72-S11-79, 1995.
46. Zoli W, Ricotti L, Barzanti F, Dal Susino M, Frassineti GL, Milandri C, Giunchi C, and Amadori D. Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines. Int J Cancer 80: 413-416, 1999.